AbbVie (NYSE:ABBV), a United States-based biopharmaceutical company, has reported its financial results for the second quarter ended 30 June 2020, it was reported on Friday.
The firm posted net revenues of USD10.425bn in the second quarter of 2020, up 26.3% compared to the year-ago period of USD8.255bn.
The company reported a net earnings loss of USD739m, diluted loss per share of USD0.46 on a GAAP Basis and an adjusted diluted EPS of USD2.34 in Q2 2020 compared with net earnings loss of USD741m, diluted loss per share of USD0.49 on a GAAP Basis and an adjusted diluted EPS of USD2.26 in Q2 2019.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government